InvestSMART

Compumedics Limited (ASX:CMP)

ALERT: Price-sensitive ASX Announcement for CMP
Current share price for CMP : $0.230 -0.01 (-4.17%)+
Announcement
Release
6 Jul 2026 10:43AM
Price at Release
$0.240
Full Release
download
Summary
Compumedics Limited reported record revenue for FY26, with shipped and invoiced revenue reaching approximately $60.3 million, representing an 18% growth from FY25. The company attributes this success to the strong performance of its sleep diagnostics, neurology, and MEG platforms, as well as its connected platforms like Somfit and Nexus 360, which saw recurring revenues increase by 70%. The company overcame challenges related to helium supply affecting MEG shipments and is preparing for the U.S. release of Somfit D. With a strong sales pipeline and existing orders, Compumedics aims for continued double-digit revenue growth in FY27 while targeting EBITDA growth at a faster rate.
Key Points
  • Record FY26 revenue of $60.3 million, 18% growth.
  • Somfit and Nexus 360 SaaS revenues grew 70% in FY26.
  • MEG platform affected by helium supply disruptions, now resolved.
  • Preparing for the commercial release of Somfit D in the USA.
  • Targeting double-digit revenue and faster EBITDA growth in FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.